A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
AVADEL PHARMACEUTICALS PLC
AVDL
$1.0B
Mkt Cap
AVADEL PHARMACEUTICALS PLC (AVDL) has a 5-year average return on invested capital (ROIC) of -66.9%. This is below average and may indicate limited pricing power.
AVADEL PHARMACEUTICALS PLC (AVDL) has a market capitalization of $2.1B. It is classified as a mid-cap stock.
AVADEL PHARMACEUTICALS PLC (AVDL) does not currently pay a regular dividend.
AVADEL PHARMACEUTICALS PLC (AVDL) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
AVADEL PHARMACEUTICALS PLC (AVDL) reported annual revenue of $169 million in its most recent fiscal year, based on SEC EDGAR filings.
AVADEL PHARMACEUTICALS PLC (AVDL) has a net profit margin of -28.9%. The company is currently unprofitable.
AVADEL PHARMACEUTICALS PLC (AVDL) generated $-47 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
(Dollar amounts in thousands, except per-share amounts, information set forth under Part III, and as otherwise noted) General Overview Avadel Pharmaceuticals plc (Nasdaq: AVDL) (“Avadel,” the “Company,” “we,” “our,” or “us”) is a biopharmaceutical company. LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. As of the date of this Annual Report, LUMRYZ is the only commercial product in our portfolio. We continue to evaluate opportunities to expand our product portfolio. LUMRYZ was approved by the FDA on May 1, 2023 for the treatment of cataplexy or EDS in adults with narcolepsy. The FDA also granted seven years of Orphan Drug Exclusivity (“ODE”) to LUMRYZ for the treatment of cataplexy or EDS in adults with narcolepsy due to a finding of clinical superiority of LUMRYZ relative to currently marketed oxybate treatments.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 249M | 169M | - | 0 | 0 | 22M |
| Net Income | -278K | -49M | -160M | -137M | -77M | 7.0M |
| EPS | $-0.00 | $-0.51 | $-2.00 | $-2.29 | $-1.32 | $0.13 |
| Free Cash Flow | 0 | -47M | -129M | -71M | -77M | 49M |
| ROIC | 53.7% | -51.0% | -170.3% | -94.4% | -30.3% | 11.7% |
| Gross Margin | 94.9% | 91.0% | - | - | - | 74.3% |
| Debt/Equity | 0.00 | 0.02 | 0.37 | -6.20 | 1.85 | 0.80 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 4.5M | -42M | -138M | -99M | -86M | 5.8M |
| Operating Margin | 1.8% | -25.1% | - | - | - | 26.0% |
| ROE | -0.3% | -60.4% | -481.4% | -481.5% | -64.3% | 10.6% |
| Shares Outstanding | 97M | 96M | 80M | 60M | 59M | 54M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | N/A | N/A | 173M | 150M | 173M | 103M | 59M | 22M | 0 | 0 | N/A | 169M | 249M |
| Gross Margin | N/A | N/A | 76.7% | 58.1% | 90.6% | 56.7% | 79.5% | 74.3% | N/A | N/A | N/A | 91.0% | 94.9% |
| R&D | 16M | 17M | 26M | 35M | 33M | 39M | 33M | 20M | 17M | 21M | 13M | 15M | 40M |
| SG&A | 13M | 16M | 22M | 44M | 59M | 100M | 30M | 32M | 68M | 75M | 152M | 181M | 191M |
| EBIT | -54M | -94M | 71M | -5.0M | 90M | -105M | -24M | 5.8M | -86M | -99M | -138M | -42M | 4.5M |
| Op. Margin | N/A | N/A | 40.9% | -3.3% | 51.7% | -101.6% | -40.7% | 26.0% | N/A | N/A | N/A | -25.1% | 1.8% |
| Net Income | -43M | -85M | 42M | -41M | 68M | -95M | -33M | 7.0M | -77M | -137M | -160M | -49M | -278K |
| Net Margin | N/A | N/A | 24.2% | -27.5% | 39.4% | -92.3% | -56.1% | 31.5% | N/A | N/A | N/A | -28.9% | -0.1% |
| Non-Recurring | -14K | 17M | 13M | -110K | 3.3M | 67M | 169K | 46M | 53K | 3.3M | 0 | 0 | 0 |
| Returns on Capital | |||||||||||||
| ROIC | -70.8% | -42.5% | 90.2% | -8.9% | 103.3% | -93.3% | -31.5% | 11.7% | -30.3% | -94.4% | -170.3% | -51.0% | 53.7% |
| ROE | -395.9% | -341.5% | 88.8% | -74.2% | 107.0% | -215.7% | 251.5% | 10.6% | -64.3% | -481.5% | -481.4% | -60.4% | -0.3% |
| ROA | -36.8% | -58.9% | 21.5% | -17.9% | 27.4% | -43.0% | -19.4% | 3.0% | -27.7% | -72.3% | -107.8% | -29.7% | -0.1% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | -21M | -11M | 84M | 19M | 17M | -83M | -38M | 49M | -77M | -70M | -129M | -47M | 35M |
| Free Cash Flow | -22M | -12M | 83M | 18M | 16M | -83M | -38M | 49M | -77M | -71M | -129M | -47M | 0 |
| Owner Earnings | -26M | -27M | 62M | -8.2M | 3.7M | -104M | -40M | 44M | -87M | -78M | -145M | -68M | 14M |
| CapEx | 1.0M | 1.7M | 1.6M | 1.2M | 591K | 178K | 29K | 98K | 26K | 716K | 0 | 0 | 0 |
| Maint. CapEx | 3.1M | 14M | 15M | 12M | 4.9M | 13M | 1.0M | 1.4M | 465K | 627K | 881K | 1.0M | 2.0M |
| Growth CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 89K | N/A | N/A | 0 |
| D&A | 3.1M | 14M | 15M | 12M | 4.9M | 13M | 1.0M | 1.4M | 465K | 627K | 881K | 1.0M | 2.0M |
| CapEx/OCF | N/A | N/A | 1.9% | 6.4% | 3.5% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 22M | 28M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | N/A | N/A | N/A | 6.5% | 29.8% | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 2.0M | 2.7M | 7.7M | 15M | 8.1M | 7.9M | 519K | 3.0M | 8.9M | 7.0M | 16M | 20M | 19M |
| Debt Repayment | 475K | 34M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.8M | 4.4M | 0 | 0 |
| Balance Sheet | |||||||||||||
| Net Debt | 79M | -81M | -140M | -153M | -94M | 16M | 60M | -91M | -12M | 35M | -72M | -72M | -92M |
| Cash & Equiv. | 6.6M | 40M | 65M | 39M | 17M | 9.3M | 9.8M | 72M | 51M | 74M | 31M | 51M | 92M |
| Long-Term Debt | 66M | 1.3M | 684K | 547K | 156K | 116M | 122M | 128M | 142M | 92M | 30M | 0 | N/A |
| Debt/Equity | -9.77 | 0.48 | 0.07 | 0.02 | 0.00 | 41.67 | -4.27 | 0.80 | 1.85 | -6.20 | 0.37 | 0.02 | 0.00 |
| Interest Coverage | -20.6 | -16.3 | N/A | -5.2 | 85.1 | -9.9 | -1.9 | 0.4 | -8.6 | -8.0 | -13.9 | -3.9 | -3.9 |
| Equity | -8.8M | 25M | 69M | 42M | 86M | 2.8M | -29M | 162M | 78M | -21M | 88M | 74M | 98M |
| Total Assets | 116M | 174M | 215M | 245M | 253M | 190M | 151M | 312M | 247M | 133M | 165M | 164M | 199M |
| Total Liabilities | 125M | 149M | 146M | 203M | 168M | 188M | 181M | 149M | 169M | 154M | 77M | 90M | 101M |
| Intangibles | 40M | 28M | 16M | 23M | 92M | 1.6M | 813K | 0 | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -236M | -320M | -279M | -320M | -263M | -358M | -391M | -384M | -448M | -585M | -745M | -794M | -790M |
| Working Capital | -7.4M | 41M | 121M | 119M | 37M | 86M | 46M | 248M | 171M | 45M | 97M | 85M | 110M |
| Current Assets | 32M | 112M | 166M | 181M | 124M | 125M | 82M | 263M | 192M | 101M | 134M | 134M | 172M |
| Current Liabilities | 40M | 71M | 45M | 62M | 87M | 38M | 36M | 15M | 21M | 56M | 37M | 49M | 62M |
| Per Share Data | |||||||||||||
| EPS | -1.69 | -2.36 | 0.96 | -1.00 | 1.63 | -2.55 | -0.89 | 0.13 | -1.32 | -2.29 | -2.00 | -0.51 | -0.00 |
| Owner EPS | -1.01 | -0.76 | 1.42 | -0.20 | 0.09 | -2.78 | -1.07 | 0.82 | -1.48 | -1.30 | -1.81 | -0.71 | 0.14 |
| Book Value | -0.35 | 0.69 | 1.59 | 1.02 | 2.04 | 0.07 | -0.78 | 3.00 | 1.34 | -0.35 | 1.09 | 0.77 | 1.01 |
| Cash Flow/Share | -0.81 | -0.29 | 1.94 | 0.46 | 0.40 | -2.21 | -1.03 | 0.90 | -1.32 | -1.17 | -1.60 | -0.49 | 0.02 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 25.4M | 36.2M | 43.5M | 41.3M | 41.9M | 37.4M | 37.3M | 54.1M | 58.6M | 60.0M | 80.1M | 95.7M | 97.2M |
| Valuation | |||||||||||||
| P/E Ratio | N/A | N/A | 15.2 | N/A | 5.0 | N/A | N/A | 51.1 | N/A | N/A | N/A | N/A | N/A |
| P/FCF | N/A | N/A | 7.7 | 22.9 | 21.3 | N/A | N/A | 7.4 | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | 7.0 | N/A | 2.8 | N/A | N/A | 45.7 | N/A | N/A | N/A | N/A | 445.0 |
| Price/Book | N/A | 24.9 | 9.2 | 9.6 | 4.0 | 33.3 | N/A | 2.2 | 6.0 | N/A | 13.3 | 13.7 | 21.4 |
| Price/Sales | N/A | N/A | 4.5 | 3.1 | 2.4 | 2.2 | 1.8 | 18.2 | N/A | N/A | N/A | 8.3 | 8.5 |
| FCF Yield | N/A | -2.0% | 13.0% | 4.4% | 4.7% | -89.4% | -14.1% | 13.5% | -16.5% | -17.9% | -11.0% | -4.6% | N/A |
| Market Cap | 0 | 621M | 636M | 405M | 342M | 93M | 272M | 359M | 467M | 396M | 1.2B | 1.0B | 2.1B |
| Avg. Price | 0.00 | 12.80 | 17.87 | 11.22 | 9.75 | 6.17 | 2.92 | 7.51 | 8.24 | 5.90 | 11.53 | 14.66 | 21.64 |
| Year-End Price | 0.00 | 17.11 | 14.61 | 9.82 | 8.17 | 2.48 | 7.28 | 6.64 | 7.98 | 6.60 | 14.59 | 10.54 | 21.64 |
AVADEL PHARMACEUTICALS PLC passes 2 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 82.6%. At current prices, the estimated annualized return to fair value is -9.6%.
AVADEL PHARMACEUTICALS PLC (AVDL) has a debt-to-equity ratio of 0.02. This indicates a conservatively financed balance sheet.
AVADEL PHARMACEUTICALS PLC (AVDL) reported earnings per share (EPS) of $-0.51 in its most recent fiscal year.
AVADEL PHARMACEUTICALS PLC (AVDL) has a return on equity (ROE) of -60.4%. A negative ROE may indicate losses or negative equity.
AVADEL PHARMACEUTICALS PLC (AVDL) has a 5-year average gross margin of 82.6%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 16 years of financial data for AVADEL PHARMACEUTICALS PLC (AVDL), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
AVADEL PHARMACEUTICALS PLC (AVDL) has a book value per share of $0.77, based on its most recent annual SEC filing.